Updates in immunotherapy for metastatic urothelial carcinoma

Metastatic urothelial carcinoma, also called advanced bladder cancer or upper-tract urothelial cancer when it begins in the renal pelvis or ureter, has entered a period of rapid treatment change. Immune checkpoint inhibitors remain central to care, while antibody–drug conjugates and molecularly targeted medicines are reshaping first-line and later-line decisions. Learn more about Adjuvant Radiotherapy For High Risk Prostate Cancer After Prostatectomy.html.

For patients in Australia, the most useful update is that immunotherapy is no longer considered a single treatment approach. The choice depends on fitness, kidney function, previous platinum chemotherapy, tumour biology, treatment availability, and the balance between disease control and quality of life. Evidence published through specialist journals such as Urological Science helps clinicians interpret these developments in everyday practice.

How first-line treatment is changing

The combination of pembrolizumab, an anti-PD-1 antibody, and enfortumab vedotin, an antibody–drug conjugate directed at Nectin-4, has become a major first-line option for advanced urothelial carcinoma. The EV-302/KEYNOTE-A39 trial showed improved progression-free and overall survival compared with platinum chemotherapy and gemcitabine in previously untreated locally advanced or metastatic disease.

This combination is particularly important because it can be used across a broad range of patients, including many who are not suitable for cisplatin. That does not make treatment straightforward. Diabetes, peripheral neuropathy, rash risk, kidney impairment, hearing loss, frailty, and autoimmune disease all influence the decision. Enfortumab vedotin can cause skin reactions, nerve symptoms, high blood glucose and eye complications, while pembrolizumab may trigger immune-related inflammation in organs such as the thyroid, bowel, lungs, liver or kidneys.

In Australia, access may depend on Therapeutic Goods Administration approval, Pharmaceutical Benefits Scheme criteria, hospital protocols and private insurance. Patients treated in Sydney, Melbourne, Brisbane, Perth or regional centres may encounter different pathways, so the oncology team should explain whether a recommended combination is available through routine funding, a clinical trial or another access scheme.

Where platinum chemotherapy still fits

Platinum-based chemotherapy has not disappeared. Cisplatin with gemcitabine remains relevant for people who are sufficiently fit and have adequate renal function, hearing and neurological status. Carboplatin with gemcitabine may be considered when cisplatin is unsuitable, although outcomes and treatment goals differ between individuals.

For patients whose disease has not progressed after four to six cycles of platinum chemotherapy, maintenance avelumab can extend disease control. This approach is based on the JAVELIN Bladder 100 study and is an important example of immunotherapy being used after chemotherapy rather than replacing it immediately. The timing matters: waiting until clear progression may mean losing an opportunity for maintenance treatment.

Kidney function is a particularly practical issue in Australia, where older adults may have chronic kidney disease, dehydration during hot weather or multiple medicines that affect renal performance. A carefully measured creatinine clearance, rather than a quick assumption based on a single blood result, can help determine whether cisplatin is safe. The plan should also consider travel from rural areas to infusion centres and the need for prompt assessment if fever, diarrhoea or breathlessness develops.

Biomarkers and treatment selection

PD-L1 testing remains relevant in selected treatment pathways, especially when an immune checkpoint inhibitor is being considered without chemotherapy for someone who cannot receive platinum. However, PD-L1 is an imperfect marker. A low score does not necessarily mean that immunotherapy will fail, and a high score does not guarantee a response.

The clinical picture is equally important. Performance status, symptom burden, liver or bone metastases, speed of progression and previous treatment all affect expected benefit. Molecular testing may identify uncommon alterations, including changes involving the FGFR pathway, that could open the door to targeted treatment. Testing is most useful when it is performed early enough to influence later-line planning.

Shared decision-making should include a realistic discussion of response patterns. Some patients experience a rapid and durable reduction in tumour burden, while others have little benefit and need a prompt change in strategy. The goal is not simply to select a modern drug; it is to match treatment intensity with the patient’s priorities, support network and ability to attend monitoring appointments.

Managing immune-related adverse effects

Checkpoint inhibitors work by releasing brakes on T-cell activity. The same mechanism can produce inflammation in healthy tissues. Thyroid dysfunction is relatively common and may require long-term hormone replacement. Less common but serious complications include immune-mediated pneumonitis, colitis, hepatitis, nephritis, myocarditis and neurological syndromes.

Patients should report new or worsening symptoms early rather than waiting for the next infusion. Persistent diarrhoea, dark urine, yellowing of the skin, severe weakness, chest pain, new cough, shortness of breath or confusion can require urgent review. In Australia, a treatment card or written plan is useful when travelling between a local GP, emergency department and tertiary cancer service.

Supportive care should begin before treatment. Vaccination advice, medication review, diabetes monitoring and skin care can reduce avoidable problems. Families often manage appointments, transport and household responsibilities alongside treatment; practical resources such as family essentials may be useful for carers balancing cancer care with young children and everyday routines, although they are separate from medical advice.

What happens after progression

When cancer progresses after checkpoint inhibition, treatment is guided by what the patient has already received and how quickly the disease is changing. Enfortumab vedotin can be used after platinum chemotherapy and immunotherapy when it was not given earlier. Sacituzumab govitecan has shown activity in previously treated disease, although regulatory status, reimbursement and availability vary by country and over time.

For tumours with actionable FGFR3 alterations, an FGFR inhibitor may be considered where approved and accessible. Clinical trials remain especially valuable for people whose cancer has progressed through platinum, immunotherapy and an antibody–drug conjugate. Trials may investigate new checkpoint combinations, bispecific antibodies, vaccines, cellular therapies and next-generation drug conjugates.

It is also important to distinguish urothelial carcinoma from other urological cancers. For example, treatment discussions about advanced prostate cancer may involve androgen deprivation rather than bladder-cancer immunotherapy; a review of androgen deprivation therapy illustrates why the tumour’s origin and biology must be established before treatment is chosen. A pathology review can be worthwhile when the clinical course is unusual or the original biopsy was limited.

Living well during advanced treatment

Symptoms from the cancer itself can be as important as scan results. Bone pain, urinary bleeding, obstruction, recurrent infection, fatigue and loss of appetite need active management. A nephrostomy, ureteric stent, catheter or palliative radiotherapy may improve comfort and preserve kidney function even when systemic therapy continues.

Not every groin or abdominal symptom signals cancer progression. A separate problem such as an inguinal hernia can cause a lump, discomfort or pain, and a hernia symptom guide may help explain why a clinical examination is necessary. Sudden severe pain, vomiting, a tender irreducible lump or abdominal distension requires urgent medical assessment.

Daily habits also influence resilience. Staying hydrated, maintaining gentle activity, protecting the skin and keeping a record of symptoms can make consultations more productive. In Australia, heat, long driving distances and limited specialist services outside capital cities may complicate care, so telehealth, local pathology testing and a clear after-hours contact number can be valuable.

Cancer care should include early palliative care, not only end-of-life support. Specialist palliative teams can help with pain, nausea, sleep, anxiety, advance care planning and family concerns while active treatment continues. Patients should also clarify the purpose of each scan and treatment cycle, including what would lead to continuing, pausing or changing therapy.

Ask the treating oncology team to review the treatment plan against current Australian approvals, funding rules and clinical-trial opportunities. Keep pathology reports, imaging results, medication lists and adverse-effect notes together, and seek urgent care for severe or rapidly worsening symptoms. Staying informed and reporting changes early can help ensure that immunotherapy is delivered safely and that every reasonable treatment option is considered.